New York, May 22, 2026, 4:02 PM EDT
- BioAge Labs closed down 0.8% at $16.61, underperforming a firmer Nasdaq Composite on Friday.
- The company said its CFO and chief strategy officer will speak at the Jefferies Global Healthcare Conference on June 4.
- Investors remain focused on BGE-102, an oral NLRP3 inhibitor, with two proof-of-concept studies planned to start around mid-2026.
BioAge Labs shares slipped on Friday, lagging a broader Wall Street rise, after the clinical-stage biotech set fresh June investor meetings but offered no new clinical data. BIOA closed at $16.61, down 0.8%, while Reuters reported the Nasdaq Composite up 0.5% in afternoon trade.
The notice was routine. The timing was not. BioAge is heading into a stretch where investors want to see whether BGE-102, its lead drug candidate, can move from early biomarker data into patient studies that matter for cardiovascular and retinal disease.
BioAge said Dov Goldstein, its chief financial officer, and BJ Sullivan, its chief strategy officer, are scheduled for a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4, with one-on-one investor meetings also planned. The company said webcasts would be archived for 30 days.
BGE-102 is an NLRP3 inhibitor, meaning it is designed to block an inflammatory protein complex that BioAge says is tied to age-related chronic inflammation. The company is developing it for cardiovascular risk and retinal diseases including diabetic macular edema, a diabetes-related eye condition that can damage vision.
The next steps are the crux. BioAge has said it plans to start a Phase 2 dose-ranging proof-of-concept trial in cardiovascular risk around mid-2026, with data expected by year-end. A proof-of-concept trial is an early study meant to show whether a drug has enough activity in patients to justify bigger trials. A Phase 1b/2a study in diabetic macular edema is also planned for mid-2026, with data expected in mid-2027.
The company’s April Phase 1 data showed at least 85% median reductions in high-sensitivity C-reactive protein, or hsCRP, a blood marker of inflammation linked to cardiovascular risk, at both 60 mg and 120 mg once-daily doses. BioAge said BGE-102 was well tolerated across dose levels and reported no serious adverse events in that trial.
Kristen Fortney, BioAge’s chief executive and co-founder, said this month that the April data “reinforce our conviction” in BGE-102 and added: “Our focus now is execution.” In the earlier data release, Fortney called the drug a potential “pipeline in a pill,” a phrase investors will likely test against the company’s trial timelines rather than take on faith. BioAge Labs, Inc.
Paul Rubin, BioAge’s chief medical officer, said hsCRP is “among the most predictive biomarkers” of cardiovascular risk and argued that a well-tolerated oral therapy could have broad use in prevention. That is still a company view, and the next studies will need to show whether the biomarker effect holds up in the settings BioAge wants to pursue. GlobeNewswire
BioAge ended March with $384.9 million in cash, cash equivalents and marketable securities, and said that should fund operations and capital expenses through 2029. First-quarter collaboration revenue rose to $2.8 million from $1.5 million a year earlier, while R&D expense rose to $20.4 million and net loss widened to $22.3 million.
Analyst interest has come back after the BGE-102 update. Insider Monkey, citing The Fly, reported this week that BTIG initiated coverage of BioAge with a Buy rating and a $40 price target, pointing to the company’s cash runway and upcoming clinical catalysts. Separately, Investing.com reported in March that Jefferies analyst Roger Song saw best-in-class potential in BGE-102 and noted the company’s runway to 2029.
The competitive backdrop has sharpened. Eli Lilly agreed in January to buy Ventyx Biosciences for $1.2 billion, a deal that gave the NLRP3 field a fresh valuation marker. Lilly said Ventyx’s pipeline includes small-molecule drugs, including NLRP3 inhibitors, for inflammatory diseases, while Reuters noted that one Ventyx drug in mid-stage testing targets a cardiovascular condition linked to obesity.
But the downside case is plain. BioAge said in its latest quarterly filing that it has not completed any clinical trials beyond Phase 1b and has no approved commercial products. It also warned that drug trials may fail to show safety or efficacy, cost more than expected, or face delays in enrollment and completion. A safety signal, a delayed trial start, or weak patient data would leave the stock exposed despite the cash balance.
Trading will pause after the long weekend, with Nasdaq closed on Monday, May 25, for Memorial Day. For BioAge, the next live market test comes after investors hear management’s June pitch and look for confirmation that the mid-2026 trial starts remain on track.
